Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6740809 | 0.81 | CHRNB2 (0.33) | CHRNB2CHRNB4CHRNA4DNM1HPGD | |
| SCHEMBL6895421 | 0.79 | ALDH1A1 (0.42) | MAPTALDH1A1 | |
| SCHEMBL7762761 | 0.77 | ALDH1A1 (0.39) | CHRNB2CHRNB4CHRNA4MAPTALDH1A1 | |
| SCHEMBL6899270 | 0.76 | PYGL (0.31) | ALDH1A1 | |
| SCHEMBL6889408 | 0.75 | CYP3A4 (0.44) | — | |
| SCHEMBL27538373 | 0.75 | CYP3A4 (0.44) | — | |
| SCHEMBL691955 | 0.72 | ALDH1A1 (0.41) | CHRNB2CHRNB4CHRNA4MAPTCA1 | |
| SCHEMBL6731438 | 0.72 | PKM (0.41) | HPGDALDH1A1PKM | |
| SCHEMBL1526306 | 0.71 | MMP1 (0.39) | CHRNB2CHRNB4CHRNA4DNM1MAPT | |
| SCHEMBL12155305 | 0.71 | USP2 (0.39) | CHRNB2CHRNB4CHRNA4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6683200-B2 | N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE IS USED AS A TUMOR NECROSIS FACTOR-ALPHA PRODUCTION INHIBITORY AGENT AND A THERAPEUTICAL AGENT FOR AUTOIMMUNE DISEASES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-01-27 | — | — | US | disclosed |
| US-20020068763-A1 | N-substituted-N'-substituted urea derivatives and pharmaceutical compositions containing the derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-06-06 | — | — | US | disclosed |
| EP-1172358-A1 | N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068763-A1 | N-substituted-N'-substituted urea derivatives and pharmaceutical compositions containing the derivatives | TNF, NFKBIA, UMPS | CHRNB2 3239/4885CHRNB4 3041/4885CHRNA4 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.